Examples of using Combination with melphalan in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
In combination with melphalan, produces more rapid benefit than MP.
Table 1: Starting doses for thalidomide in combination with melphalan and prednisone.
When used in combination with melphalan and prednisone, Velcade is given twice a week on weeks 1, 2, 4 and 5 of a six-week treatment cycle.
Table 2: Recommended posology for VELCADE in combination with melphalan and prednisone.
Lenalidomide in combination with melphalan and prednisone followed by maintenance monotherapy in patients who are not eligible for transplant.
Frequency of adverse reactions with thalidomide in combination with melphalan and prednisone.
Recommended posology for VELCADE in combination with melphalan and prednisone for patients with previously untreated multiple myeloma Twice weekly VELCADE cycles 1-4.
Newly diagnosed multiple myeloma in patients treated with lenalidomide in combination with melphalan and prednisone.
In these patients, Velcade is used in combination with melphalan and prednisone; previously untreated patients who are going to receive high-dose chemotherapy followed by a blood stem-cell transplant.
Table 3: Posology modifications during subsequent cycles of VELCADE therapy in combination with melphalan and prednisone.
Thalidomide Celgene in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged≥ 65 years or ineligible for high dose chemotherapy.
Newly diagnosed multiple myeloma patients treated with lenalidomide in combination with melphalan and prednisone.
VELCADE in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.
Dose modification andre-initiation of therapy when VELCADE is administered in combination with melphalan and prednisone.
In September 2008, Velcade® was approved in combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.
Beromun has been studied in four main studies involving a total of 188 patients,in which it was given in combination with melphalan.
Venous thromboembolism was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone in newly diagnosed multiple myeloma.
The study compared lenalidomide in combination with melphalan and prednisone(MPR) with or without lenalidomide maintenance monotherapy until disease progression, to that of melphalan and prednisone for a maximum of 9 cycles.
No dose adjustment is proposed for patients older than 75 years who are treated with lenalidomide in combination with melphalan and prednisone.
Thalidomide Celgene is used to treat multiple myeloma(a cancer of the bone marrow) in combination with melphalan and prednisone(anticancer medicines) in patients who have not been treated for multiple myeloma before.
Dose adjustments for combination therapy Dose modification andre-initiation of therapy when VELCADE is administered in combination with melphalan and prednisone.
Among invasive SPMs,cases of MDS/AML were observed in patients receiving lenalidomide in combination with melphalan or immediately following high dose melphalan and autologous stem cell transplantation.
The benefit achieved with thalidomide and the risk of AML and MDS must be taken into account before initiating treatment with thalidomide in combination with melphalan and prednisone.
Thalidomide Celgene istaken in treatment cycles, each cycle lasting 6 weeks, in combination with melphalan and prednisone which are taken on days 1 to 4 of each 6 week cycle.
Overall, the safety profile of patients treated with VELCADE in monotherapy was similar to that observed in patients treated with VELCADE in combination with melphalan and prednisone.
Venous thromboembolism was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone in newly diagnosed multiple myeloma and with monotherapy in myelodysplastic syndromes.
This increase was not observed in clinical trials of newly diagnosed multiple myeloma in patients taking lenalidomide in combination with low dose dexamethasone compared to thalidomide in combination with melphalan and prednisone.
VELCADE in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Treatment emergent drug-related adverse reactions reported in≥ 10% of patients treated with VELCADE in combination with melphalan and prednisone Vc+M+P M+P.
The most commonly observed adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone are: neutropenia, leukopenia, constipation, somnolence, paraesthesia, peripheral neuropathy, anaemia, lymphopenia, thrombocytopenia, dizziness, dysaesthesia, tremor and peripheral oedema.